Efficacy and safety of bioresorbable vascular scaffold Absorb: 6-month outcomes of GABI-R: Russia registry
Published 2019-05-02
Keywords
- bioresorbable vascular scaffold,
- coronary artery disease,
- coronary stenting ischemic heart disease,
- revascularization
How to Cite
Copyright (c) 2019 Prokhorikhin A. A., Fartakov E. I., Malaev D. U., Boykov A. A., Oidup-Ool S. V., Baystrukov V. I., Grazhdankin I. O., Zubarev D. D., Pokushalov E. A., Kretov E. I.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Abstract
Aim. The paper demonstrates the interim analysis of efficacy and safety after everolimus-eluting bioresorbable vascular scaffold (BVS) Absorb implantation in “real-world patients” with coronary artery disease.
Methods. A cohort of 500 consecutive patients who underwent percutaneous coronary intervention for stable chest pain or acute coronary syndrome with implantation of at least one BVS (Absorb, Abbott Vascular) and followed up by telephone interview and review of medical charts were included in a singlecenter, prospective, all-comers, first in Russia registry. The primary endpoint, target vessel failure, defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target vessel revascularization and secondary endpoints, MACCE (composite of cardiovascular death, myocardial infarction, coronary artery bypass surgery, target vessel revascularization, stroke) and stent thrombosis, were assessed during 6-month follow-up.
Results. A total of 500 patients with coronary artery disease (CAD) (stable CAD 54.4%, acute coronary syndrome 45.6%) and different amount of affected vessels (1 vessel CAD 40.8%, n = 204; 2-vessel CAD 32.8%, n = 164; 3-vessel CAD 26.4%, n = 132) received 664 scaffolds and 55 stents in 603 stenoses. Procedure success, defined as a residual stenosis less than 30% and TIMI 3 flow in target vessel at the end of procedure, was observed in 98.51% (n = 594). At the moment of 6-month follow-up 4.2% (n = 24) of patients were lost to contact. After 6 months, incidence of target vessel failure and MACCE was 4.2% (n = 21) and 5% (n = 25). The cumulative rate of definite/probable scaffold thrombosis was 1.6% (n = 8).
Conclusion. The interim analysis of Gabi-R: Russia registry, the largest trial of BVS Absorb implantation in routine clinical practice, showed high procedural success and low incidence of adverse events during follow-up. However, a tendency to high incidence of scaffold thrombosis compared to drug-eluting stents can be observed. Considering the long-term results of randomized trials retrospective registries, safety in terms of BVS routine use is of big concern. Longterm 24-month data regarding safety endpoints are required to test the afore-mentioned suggestion.
Received 5 January 2019. Revised 28 March 2019. Accepted 29 March 2019.
Funding: The study did not have sponsorship.
Conflict of interest: Authors declare no conflict of interest.
References
- Navarese E.P., Kowalewski M., Kandzari D., Lansky A., Górny B., Kołtowski L., Waksman R., Berti S., Musumeci G., Limbruno U., van der Schaaf R.J., Kelm M., Kubica J., Suryapranata H. Firstgeneration versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart. 2014 21;1(1):e000064. eCollection 2014. PMID: 25332803 PMCID: PMC4189321 https://doi.org/10.1136/openhrt-2014-000064
- Habara S., Kadota K., Kuwayama A., Shimada T., Ohya M., Miura K., Amano H., Kubo S., Hyodo Y., Otsuru S., Tada T., Tanaka H., Fuku Y., Goto T. Late Restenosis After Both First-Generation and Second-Generation Drug-Eluting Stent Implantations Occurs in Patients With Drug-Eluting Stent Restenosis. Circ Cardiovasc Interv. 2016;9(12). pii: e004449. PMID: 27932532 https://doi.org/10.1161/CIRCINTERVENTIONS.116.004449
- Cassese S., Byrne R.A., Ndrepepa G., Kufner S., Wiebe J., Repp J., Schunkert H., Fusaro M., Kimura T., Kastrati A. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016;387(10018):537-44. PMID: 26597771 https://doi.org/10.1016/S0140-6736(15)00979-4
- Capodanno D., Gori T., Nef H., Latib A., Mehilli J., Lesiak M., Caramanno G., Naber C., Di Mario C., Colombo A., Capranzano P., Wiebe J., Araszkiewicz A., Geraci S., Pyxaras S., Mattesini A., Naganuma T., Münzel T., Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10(10):1144- 53. PMID: 25042421 https://doi.org/10.4244/EIJY14M07_11
- Grove E.C.L., Kristensen S.D. Stent thrombosis: definitions, mechanisms and prevention. E-journal of Cardiology Practice. 2007;5(32). 08 May 2007.
- Ellis S.G., Kereiakes D.J., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., Litt M.R., Kini A., Kabour A., Marx S.O., Popma J.J., McGreevy R., Zhang Z., Simonton C., Stone G.W.; ABSORB III Investigators. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med. 2015;373(20):1905-15. PMID: 26457558 https:// doi.org/10.1056/NEJMoa1509038
- Gao R., Yang Y., Han Y., Huo Y., Chen J., Yu B., Su X., Li L., Kuo H.C., Ying S.W., Cheong W.F., Zhang Y., Su X., Xu B., Popma J.J., Stone G.W.; ABSORB China Investigators.. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial. J Am Coll Cardiol. 2015;66(21):2298-2309. PMID: 26471805 https://doi.org/10.1016/j.jacc.2015.09.054
- Serruys P.W., Chevalier B., Sotomi Y., Cequier A., Carrié D., Piek J.J., Van Boven A.J., Dominici M., Dudek D., McClean D., Helqvist S., Haude M., Reith S., de Sousa Almeida M., Campo G., Iñiguez A., Sabaté M., Windecker S., Onuma Y. Comparison of an everolimuseluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388(10059):2479-2491. PMID: 27806897 https://doi.org/10.1016/S0140-6736(16)32050-5
- Ellis S., Kereiakes D., Stone G. Everolimuseluting bioresorbable vascular scaffolds in patients with coronary artery disease: ABSORB III trial 2-year results. Paper presented at: American College of Cardiology’s Annual Scientific Session; March 17–19, 2017; Washington, DC.
- Varenhorst C., Lindholm M., Sarno G., Olivecrona G., Jensen U., Nilsson J., Carlsson J., James S., Lagerqvist B. Stent thrombosis rates the first year and beyond with new-and old-generation drug-eluting stents compared to bare metal stents. Clin Res Cardiol. 2018;107(9):816- 823. PMID: 29667015 PMCID: PMC6105307 https://doi.org/10.1007/s00392-018-1252-0
- Onuma Y., Kukreja N., Piazza N., Eindhoven J., Girasis C., Schenkeveld L., van Domburg R., Serruys P.W.; Interventional Cardiologists of the Thoraxcenter (2000 to 2007). The everolimus-eluting stent in realworld patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol. 2009;54(3):269-76. PMID: 19589442 https://doi.org/10.1016/j.jacc.2009.05.016